Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Profile

Rangaswamy Govindarajan

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
164
0.830
 Why?
Anus Neoplasms
1
2018
33
0.650
 Why?
Bone Marrow Neoplasms
1
2015
15
0.550
 Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1056
0.550
 Why?
Embolism
1
2015
27
0.550
 Why?
Gene Regulatory Networks
1
2016
124
0.530
 Why?
Tumor Lysis Syndrome
1
2014
6
0.520
 Why?
Carcinoma, Squamous Cell
1
2018
384
0.500
 Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
70
0.490
 Why?
Neoplasm Recurrence, Local
1
2018
644
0.480
 Why?
Pyrazoles
1
2014
110
0.480
 Why?
Pyrimidines
1
2014
196
0.460
 Why?
Angiogenesis Inhibitors
2
2006
203
0.440
 Why?
Salvage Therapy
1
2013
145
0.440
 Why?
Biliary Tract Diseases
1
2012
12
0.440
 Why?
Actinomycosis
1
2012
10
0.440
 Why?
Stomach Neoplasms
1
2015
173
0.440
 Why?
Clinical Trials as Topic
5
2019
490
0.440
 Why?
Bile Duct Neoplasms
1
2012
33
0.430
 Why?
Benzenesulfonates
2
2011
12
0.400
 Why?
Prognosis
6
2019
2118
0.390
 Why?
Gene Expression Profiling
1
2016
1138
0.390
 Why?
Middle Aged
12
2020
13070
0.380
 Why?
Carcinoma, Hepatocellular
1
2013
203
0.380
 Why?
Stroke
1
2015
524
0.370
 Why?
Pyridines
2
2011
137
0.350
 Why?
Colorectal Neoplasms
2
2003
235
0.350
 Why?
Liver Neoplasms
1
2013
352
0.340
 Why?
Aged, 80 and over
6
2018
3429
0.300
 Why?
Drug Industry
1
2007
40
0.300
 Why?
Heparin
1
2007
97
0.300
 Why?
Hypertensive Encephalopathy
1
2006
4
0.300
 Why?
raf Kinases
1
2006
5
0.290
 Why?
Communication Barriers
1
2007
37
0.290
 Why?
Thrombocytopenia
1
2007
99
0.290
 Why?
Thiazolidinediones
1
2007
95
0.290
 Why?
Aged
9
2020
10041
0.270
 Why?
Thrombosis
1
2007
243
0.250
 Why?
Anticoagulants
1
2007
270
0.250
 Why?
Adult
9
2020
14182
0.240
 Why?
Skin
1
2007
469
0.240
 Why?
Enzyme Inhibitors
1
2006
446
0.240
 Why?
Female
11
2020
28418
0.230
 Why?
Survival Rate
2
2018
951
0.230
 Why?
Prostatic Neoplasms
1
2007
415
0.230
 Why?
Humans
16
2020
54246
0.220
 Why?
Camptothecin
1
2002
16
0.220
 Why?
Follow-Up Studies
3
2019
2387
0.210
 Why?
Male
10
2020
27312
0.200
 Why?
Antineoplastic Agents, Phytogenic
1
2002
87
0.200
 Why?
Diabetes Mellitus, Type 2
1
2007
481
0.200
 Why?
Oximes
1
2020
12
0.190
 Why?
Lung Neoplasms
1
2007
642
0.190
 Why?
Pyrimidinones
1
2020
19
0.190
 Why?
Pyridones
1
2020
41
0.190
 Why?
Thalidomide
1
2002
397
0.180
 Why?
Imidazoles
1
2020
142
0.180
 Why?
Cholangiocarcinoma
2
2011
30
0.170
 Why?
Protein Kinase Inhibitors
1
2020
216
0.170
 Why?
Survival Analysis
3
2020
735
0.150
 Why?
Melanoma
1
2020
313
0.150
 Why?
Antineoplastic Agents
2
2019
1300
0.150
 Why?
Neoplasm Staging
2
2013
806
0.140
 Why?
Combined Modality Therapy
1
2018
692
0.140
 Why?
Severity of Illness Index
1
2019
1084
0.130
 Why?
Gene Amplification
1
2015
57
0.130
 Why?
Adenine
1
2014
44
0.130
 Why?
Polycomb Repressive Complex 2
1
2015
50
0.130
 Why?
Genes, myc
1
2015
47
0.130
 Why?
Skin Neoplasms
1
2020
532
0.130
 Why?
Antibodies, Monoclonal
1
2019
562
0.120
 Why?
Retrospective Studies
3
2018
6432
0.120
 Why?
Piperidines
1
2014
103
0.120
 Why?
Registries
3
2007
553
0.120
 Why?
United States
3
2019
5200
0.120
 Why?
Gene Deletion
1
2015
293
0.120
 Why?
Quinazolines
1
2013
39
0.110
 Why?
Leukemia, Myeloid, Acute
1
2015
191
0.110
 Why?
Treatment Outcome
4
2020
5604
0.110
 Why?
Actinomyces
1
2012
9
0.110
 Why?
Endoscopy, Gastrointestinal
1
2012
75
0.110
 Why?
Gene Expression Regulation, Neoplastic
1
2016
866
0.100
 Why?
Gallbladder Neoplasms
1
2011
5
0.100
 Why?
Comorbidity
2
2019
663
0.100
 Why?
Phenylurea Compounds
2
2011
16
0.100
 Why?
Antibodies, Monoclonal, Humanized
1
2013
240
0.100
 Why?
Niacinamide
2
2011
25
0.100
 Why?
Incidence
2
2019
1082
0.090
 Why?
Neoplasms
1
2019
1315
0.080
 Why?
Causality
1
2007
46
0.080
 Why?
Drugs, Investigational
1
2007
17
0.080
 Why?
Necrosis
1
2007
208
0.080
 Why?
Hospitals, University
1
2007
89
0.070
 Why?
Confidence Intervals
1
2007
167
0.070
 Why?
United States Food and Drug Administration
1
2007
97
0.070
 Why?
Neoplasm Metastasis
2
2011
252
0.070
 Why?
Probability
1
2007
176
0.070
 Why?
Age Distribution
1
2007
198
0.070
 Why?
Tomography, X-Ray Computed
1
2012
1213
0.070
 Why?
Anti-Bacterial Agents
1
2012
820
0.070
 Why?
Medical Oncology
1
2007
102
0.070
 Why?
Syndrome
1
2006
252
0.070
 Why?
Patient Selection
1
2007
286
0.070
 Why?
Publication Bias
1
2005
12
0.070
 Why?
Editorial Policies
1
2005
11
0.060
 Why?
Periodicals as Topic
1
2005
65
0.060
 Why?
Dose-Response Relationship, Drug
1
2007
1476
0.060
 Why?
Risk Assessment
1
2007
1361
0.050
 Why?
MAP Kinase Kinase Kinases
1
2020
18
0.050
 Why?
Socioeconomic Factors
1
2003
637
0.050
 Why?
Mutation, Missense
1
2020
117
0.050
 Why?
Proto-Oncogene Proteins B-raf
1
2020
90
0.050
 Why?
Trisaccharides
1
2019
1
0.040
 Why?
Drug Administration Schedule
1
2020
401
0.040
 Why?
Premedication
1
2019
18
0.040
 Why?
Administration, Oral
1
2020
459
0.040
 Why?
Magnetic Resonance Imaging
1
2006
1604
0.040
 Why?
Infusions, Intravenous
1
2019
231
0.040
 Why?
Antibodies
1
2019
178
0.040
 Why?
Health Services Accessibility
1
2003
431
0.040
 Why?
Disease Management
1
2019
184
0.040
 Why?
Arkansas
1
2003
2094
0.040
 Why?
Adolescent
1
2007
6885
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2015
278
0.030
 Why?
Polymorphism, Single Nucleotide
1
2015
552
0.030
 Why?
Young Adult
1
2020
4308
0.020
 Why?
Disease-Free Survival
1
2011
485
0.020
 Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (127) concept(s)
_
Co-Authors Expand Description
See all (1) people
_
Similar People Expand Description
See all (30) people
_
Same Department Expand Description
Search Department